Matched related donor allo-SCT is the treatment of choice for patients with severe aplastic anemia (SAA) younger than 40 years of age. The standard conditioning regimen for such patients is cyclophosphamide with antithymocyte globulin. Unmanipulated BM is the best stem cell source for aplastic anemia patients going for SCT. Post-transplant GVHD prophylaxis with cyclosporine should be continued for 1 year. Early graft failure is rare but potentially life-threatening complication of SCT that can be managed with salvage SCT using more intense conditioning regimen.
CANDIDATES FOR HLA-IDENTICAL SIBLING TRANSPLANTATION
Allogeneic hematopoietic SCT (HSCT) is the only available potentially curative treatment option for severe aplastic anemia (SAA). This should be the upfront therapeutic option of choice for young patients with SAA and for older patients who have failed previous immunosuppressive therapy (IS). Currently, the expected 5 year survival of HLA-identical sibling transplantation as the primary treatment modality for SAA is around 80% and reaches up to 90% in young patients.
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The outcome of allogeneic HSCT has improved remarkably during the last decade as a function of improvement of all aspects of transplantation supportive care. Accordingly, the difference in projected survival between patients treated with HSCT and IS is increasing with time in favor of HSCT over IS. Presently, most centers offer upfront allogeneic transplantation for SAA patients with an available matched sibling donor up to the age of 50 years and selected patients older than 50 who are otherwise in excellent health with disease features suggestive of low likelihood of response to IS therapy, such as very severe AA (ANC below 0.2 Â 10 9 /L).
CONDITIONING PREPARATIVE REGIMENS
Being a non-neoplastic hematologic disorder, the main goal of transplantation in aplastic anemia is to achieve successful engraftment optimally with no acute or chronic GVHD.
Despite significant progress in the structure of conditioning regimens, graft failure remains a significant concern in this disease, particularly in previously transfused patients, hence the importance of adequate lymphoablative and immunoablative components of the preparative regimen. The addition of ATG to cyclophosphamide given at a total dose of 200 mg/kg has been demonstrated to promote excellent engraftment and long-term outcome. In a non-randomized trial, this combination resulted in a lower incidence of GVHD and improved survival compared with historical controls who received cyclophosphamide only conditioning. 3, 4 Presently, this combination is more or less considered the standard conditioning regimen for SAA in the setting of matched related transplantation.
It is noteworthy that one prospective randomized trial involving 134 patients did not show a significant benefit from the addition of ATG. 5 For patients between the ages of 30 and 50 years who are potential transplantion candidates, the best conditioning regimen is not known. Patients who are 440 years of age and who are medically fit enough for HSCT, may receive a reduced intensity conditioning regimen, using cyclophosphamide 1200 mg/m 2 , fludarabine 120 mg/m 2 and either ATG or alemtuzumab. [6] [7] [8] A similar approach may be considered for patients aged 30-40 years. This approach needs confirmation in larger studies. Prevention of graft failure can be accomplished by the use of other more intense conventional conditioning, including radiation-based regimens. However, this can be counteracted by higher transplant-related morbidity and mortality in a disease where the primary goal of transplantation is to secure adequate and durable engraftment only and where there is no malignancy to be eradicated by high-dose chemo-radiotherapy or the graft versus malignancy effect. 1 STEM CELL SOURCE Unmanipulated BM should be used as the stem cell source for all patients with aplastic anemia, as the use of PBSCs is associated with increased risk of chronic GVHD. Despite the early engraftment with the use of PBSCs, a joint EBMT/CIBMTR retrospective analysis suggests inferior outcome with the use of PBSC in this disease, particularly in young patients. 9 Survival advantage for BM graft was also confirmed in a more recent report in all age groups. 10 This does not support the current trend of increasing use of PBSCs as a graft source in this disease. Adequate BM stem cell dose is expected to be associated with improved outcome.
A BM stem cell dose of at least 3 Â 10 8 mononuclear cells/kg or 2 Â 10 6 CD34 þ cells/kg should be given as a low stem cell dose increases the risk of graft failure.
Peripheral blood is an alternative stem cell source if a BM harvest is contra-indicated or if the donor is not willing to donate BM.
POST-TRANSPLANTATION IMMUNOSUPPRESSION
Adequate post-transplantation immunosuppression is important not only for the prevention of GVHD but also to secure adequate suppression of the host immune system and prevention of graft rejection. The combination of CsA and short-course MTX should be considered the standard post-transplantation immunosuppression. In a prospective randomized trial comparing CsA þ MTX with CsA alone, the 1-year TRM rates for patients given CsA/MTX or CsA alone were 3% and 15%, respectively.
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The 5-year probability of survival was 94% in the CsA/MTX group and 78% for those in the CsA-alone group. Few reports have been published about the use of other immunosuppressive agents, including the use of mycophenolate mofetil particularly in patients with renal impairment, but these data remain limited.
Slow and linear taper of CsA should be carried out with careful follow-up of chimerism and blood counts to avoid graft rejection.
